Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene versus estradiol during growth hormone replacement in hypopituitary women
ACTRN12605000532606Phase 4Active, not recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Sep 2002
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of raloxifene, estradiol and somatropin in hypopituitarism, growth hormone deficiency (GHD) and Hypogonadism (2 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoints: Short-term biochemical markers of the GH-IGF axis, substrate metabolism, and protein turnover and Long-term body composition by DEXA. Started Sep 2002; status: active, not recruiting.
02
Drugs
raloxifeneestradiolsomatropin
03
Conditions
hypopituitarismgrowth hormone deficiency (GHD)Hypogonadism
Beyond the preview
Go deeper on ACTRN12605000532606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000532606.